- Home
- IDR vs ZOM Comparison
IDR vs ZOM Comparison
Compare IDR & ZOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- ZOM
- Stock Information
- Founded
- IDR 1996
- ZOM 2015
- Country
- IDR United States
- ZOM United States
- Employees
- IDR N/A
- ZOM N/A
- Industry
- IDR Precious Metals
- ZOM Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- ZOM Health Care
- Exchange
- IDR Nasdaq
- ZOM Nasdaq
- Market Cap
- IDR 142.7M
- ZOM 128.4M
- IPO Year
- IDR N/A
- ZOM N/A
- Fundamental
- Price
- IDR $12.66
- ZOM $0.12
- Analyst Decision
- IDR Strong Buy
- ZOM
- Analyst Count
- IDR 1
- ZOM 0
- Target Price
- IDR $14.00
- ZOM N/A
- AVG Volume (30 Days)
- IDR 177.8K
- ZOM 3.3M
- Earning Date
- IDR 03-24-2025
- ZOM 03-31-2025
- Dividend Yield
- IDR N/A
- ZOM N/A
- EPS Growth
- IDR 344.27
- ZOM N/A
- EPS
- IDR 0.52
- ZOM N/A
- Revenue
- IDR $21,955,008.00
- ZOM $26,727,000.00
- Revenue This Year
- IDR $86.37
- ZOM $10.28
- Revenue Next Year
- IDR $11.11
- ZOM $28.00
- P/E Ratio
- IDR $25.24
- ZOM N/A
- Revenue Growth
- IDR 64.93
- ZOM 11.33
- 52 Week Low
- IDR $6.91
- ZOM $0.12
- 52 Week High
- IDR $18.35
- ZOM $0.20
- Technical
- Relative Strength Index (RSI)
- IDR 48.80
- ZOM 41.88
- Support Level
- IDR $12.82
- ZOM $0.12
- Resistance Level
- IDR $13.45
- ZOM $0.12
- Average True Range (ATR)
- IDR 0.67
- ZOM 0.00
- MACD
- IDR -0.13
- ZOM 0.00
- Stochastic Oscillator
- IDR 1.08
- ZOM 3.03
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.